Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-07-03 Share Issue/Capital Cha…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于拟减少公司注册资本并修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding a proposed reduction in the company's registered capital and corresponding amendments to the company's articles of association. It details the decrease in share capital due to the repurchase and cancellation of restricted shares from an employee who voluntarily left. The document includes specific changes in share numbers and capital amounts, references relevant laws and stock exchange rules, and mentions that the amendments require shareholder approval. The document is short (949 characters) and serves as a formal announcement of a capital change rather than a full financial report or detailed analysis. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2024-07-03 Chinese
关于2023年股权激励计划回购注销部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the repurchase and cancellation of restricted shares under the company's 2023 equity incentive plan. It details the board and supervisory committee meetings, the repurchase price, quantity, and the impact on share capital and equity structure. It also includes management's analysis of the repurchase's impact on financial status and creditor protection measures. The document is a formal announcement of a share repurchase related to an equity incentive plan, not a financial report or earnings release. It fits the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2024-07-03 Chinese
第四届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the fourth board of directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting's attendance, agenda items, voting results, and references to related announcements on the stock exchange platform. The content focuses on board decisions regarding stock repurchase, capital reduction, employee recognition, and scheduling a shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and it is not a report publication announcement or certification. Therefore, the appropriate classification is MANG with high confidence.
2024-07-03 Chinese
关于调整2023年股权激励计划限制性股票回购价格及预留授予价格的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the adjustment of the 2023 equity incentive plan's restricted stock repurchase price and reserved grant price by Sichuan Zitonggong Pharmaceutical Co., Ltd. It details board and supervisory meetings, approvals, legal opinions, and the rationale for the price adjustment following the 2023 annual dividend distribution. The document does not contain financial statements or comprehensive financial data but rather focuses on corporate governance and equity incentive plan adjustments. It is a regulatory announcement about changes in the equity incentive plan, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS). The document length is under 5,000 characters and is an announcement of a corporate action rather than a full report.
2024-07-03 Chinese
关于公司及子公司取得实用新型专利证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the company and its subsidiary obtaining two utility model patent certificates issued by the National Intellectual Property Office. It includes details about the patents and their significance to the company. There is no financial data, no mention of financial results, no regulatory certifications, or meeting-related information. The document is a regulatory announcement about intellectual property achievements, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not related to management changes, voting results, or capital changes. Given the nature of the content and the absence of other specific categories, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-07-03 Chinese
2023年股权激励计划预留限制性股票授予激励对象名单
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the 2023 equity incentive plan reserved restricted stock grant list for incentive recipients. It details the allocation of restricted stock under the equity incentive plan, including the number of shares, proportions, and the list of core employees receiving the grants. The document is short (1217 characters) and focuses on equity incentive plan details and employee stock grants. It is not a full financial report, audit, or earnings release. It is also not a proxy solicitation or voting result announcement. The content fits best under a Capital/Financing Update (CAP) as it relates to equity incentive plans and stock grants, which are capital structure related updates.
2024-07-03 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.